Comparison of percutaneous radiofrequency ablation and CyberKnife® for initial solitary hepatocellular carcinoma: A pilot study

Table 1 Patient characteristics

Variable	RFA (n = 38)	CyberKnief® (n = 35)	P value
Observation period	561 (range 222-1223)	379 (range 203-1065)	0.15
Age (yr), mean ± SD	68.7 ± 10.5 (range 42-86)	75.1.7 ± 8.1 (range 55-89)	0.005
Gender			0.82
Male/female	27/11	24/11
Etiology			0.32
HBV/HCV/alchol/other	9/18/3/8	4/23/1/7
Child-Push classification, A/B	31/7	28/7	0.86
Tumor size	17.5 ± 6.1 (range 7-29)	28.6 ± 11.5 (range 12-50)	0.001

P < 0.05, statistical significant. RFA: Radiofrequency ablation; HBV: Hepatitis B virus; HCV: Hepatitis C virus.

Table 2 Risk factor of intrahepatic distant recurrence in the radiofrequency ablation group

	RFA
	Distant recurrence (-)	Distant recurrence (+)	P value
n	29	9
Tumor size (mm)	17.4 ± 6.2	17.8 ± 6.0	0.87

Data are expressed as the mean ± SD. RFA: Radiofrequency ablation.

Table 3 Risk factor of intrahepatic distant recurrence in the CyberKnife^® group

	CyberKnife®
	Distant recurrence (-)	Distant recurrence (+)	P value
n	28	7
Tumor size (mm)	26.6 ± 11.1	36.3 ± 10.6	0.045
Total dose (Gy)	50.6 ± 7.8	43.6 ± 6.7	0.036

Data are expressed as the mean ± SD. P < 0.05, statistical significant.